Clinical Trials Browser

Withdrawn × Triple Negative Breast Neoplasms × Taxes × Clear all

NCT05177796 2024-10-24

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04249167 2023-01-06

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms